Beyfortus Approved to Prevent RSV Disease in Infants and Toddlers
Beyfortus (nirsevimab-alip) is approved for the prevention of RSV lower respiratory tract disease in infants and children up to 24 months of age.
Stay updated with breaking news from Thomas Triomphe. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Beyfortus (nirsevimab-alip) is approved for the prevention of RSV lower respiratory tract disease in infants and children up to 24 months of age.
The new monoclonal antibody carries a broader indication than the existing vaccine against RSV for infants.
Respiratory syncytial virus is the leading cause of hospitalization in American infants.
Respiratory syncytial virus is the leading cause of hospitalization in American infants.
AstraZeneca and Sanofi stated that a single dose demonstrated “high and consistent efficacy” against RSV LRTD and that they plan to make Beyfortus available in the U.S. by the fall.